Skip to content

Study · Other design · n = 238 · 2024

12 results

[Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation].

Kalinin MN, Khasanova DR

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2024Cited by 5 (Europe PMC)

PMID38512096 (opens in a new tab)DOI10.17116/jnevro202412403255 (opens in a new tab)PepBankPUB-38512096
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanOther designOther

    In stroke patients, Cerebrolysin treatment effects on symptomatic hemorrhagic transformation showed moderate heterogeneity.

    In plain wordsIn stroke patients, Cerebrolysin effects on symptomatic bleeding showed moderate variation.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSymptomatic HT treatment heterogeneity
    Study

    n = 238

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    I2
    36.98 to 69.3%
    symptomatic HT
    H2
    1.59 to 3.26
    symptomatic HT

    Source sentences

    Summary
    Heterogeneity of Cerebrolysin treatment effects was moderate (I2=36.98-69.3%, H2=1.59-3.26) and mild (I2=18.33-32.39%, H2=1.22-1.48) for symptomatic and any HT, respectively.
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  2. 02HumanOther designOther

    In stroke patients, Cerebrolysin treatment effects on any hemorrhagic transformation showed mild heterogeneity.

    In plain wordsIn stroke patients, Cerebrolysin effects on any bleeding showed mild variation.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableAny HT treatment heterogeneity
    Study

    n = 238

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    I2
    18.33 to 32.39%
    any HT
    H2
    1.22 to 1.48
    any HT

    Source sentences

    Summary
    Heterogeneity of Cerebrolysin treatment effects was moderate (I2=36.98-69.3%, H2=1.59-3.26) and mild (I2=18.33-32.39%, H2=1.22-1.48) for symptomatic and any HT, respectively.
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  3. 03HumanOther designSafety outcome

    In stroke patients with moderate HT risk, Cerebrolysin had a positive effect on hemorrhagic transformation.

    In plain wordsIn stroke patients with moderate bleeding risk, Cerebrolysin had a favorable effect on bleeding.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseHT at moderate risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A positive impact of the Cerebrolysin treatment on HT and functional outcome was observed in patients with moderate (HTI=1) and high (HTI≥2) HT risk.
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  4. 04HumanOther designEfficacy outcome

    In stroke patients with moderate HT risk, Cerebrolysin had a positive effect on functional outcome.

    In plain wordsIn stroke patients with moderate bleeding risk, Cerebrolysin had a favorable effect on function.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctional outcome at moderate risk
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A positive impact of the Cerebrolysin treatment on HT and functional outcome was observed in patients with moderate (HTI=1) and high (HTI≥2) HT risk.
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  5. 05HumanOther designSafety outcome

    In stroke patients with HTI=0, Cerebrolysin reduced symptomatic HT by 3.8%, without statistical significance.

    In plain wordsIn stroke patients with low bleeding risk, Cerebrolysin did not significantly reduce symptomatic bleeding.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeSymptomatic HT at low risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Symptomatic HT reduction
    3.8%
    HTI=0
    p value for Cerebrolysin treatment effect on symptomatic HT
    0.12
    Cerebrolysin treatment effect within HTI=0

    Source sentences

    Summary
    In high HT risk patients, there was a steady decline in the rate of symptomatic (HTI=0 vs. HTI≥2: by 3.8%, p=0.120 vs. 14.3%, pp=0.864 vs. 19.5%, p<0.001).
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  6. 06HumanOther designSafety outcome

    In stroke patients with HTI≥2, Cerebrolysin reduced symptomatic HT by 14.3%.

    In plain wordsIn stroke patients with high bleeding risk, Cerebrolysin reduced symptomatic bleeding.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSymptomatic HT at high risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Symptomatic HT reduction
    14.3%
    HTI≥2
    p value for Cerebrolysin treatment effect on symptomatic HT
    < 0.001
    Cerebrolysin treatment effect within HTI≥2

    Source sentences

    Summary
    In high HT risk patients, there was a steady decline in the rate of symptomatic (HTI=0 vs. HTI≥2: by 3.8%, p=0.120 vs. 14.3%, pp=0.864 vs. 19.5%, p<0.001).
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  7. 07HumanOther designSafety outcome

    In stroke patients with HTI=0, Cerebrolysin reduced any HT by 0.6%, without statistical significance.

    In plain wordsIn stroke patients with low bleeding risk, Cerebrolysin did not significantly reduce any bleeding.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeAny HT at low risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Any HT reduction
    0.6%
    HTI=0
    p value for Cerebrolysin treatment effect on any HT
    0.864
    Cerebrolysin treatment effect within HTI=0

    Source sentences

    Summary
    In high HT risk patients, there was a steady decline in the rate of symptomatic (HTI=0 vs. HTI≥2: by 3.8%, p=0.120 vs. 14.3%, pp=0.864 vs. 19.5%, p<0.001).
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  8. 08HumanOther designSafety outcome

    In stroke patients with HTI≥2, Cerebrolysin reduced any HT by 19.5%.

    In plain wordsIn stroke patients with high bleeding risk, Cerebrolysin reduced any bleeding.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAny HT at high risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Any HT reduction
    19.5%
    HTI≥2
    p value for Cerebrolysin treatment effect on any HT
    < 0.001
    Cerebrolysin treatment effect within HTI≥2

    Source sentences

    Summary
    In high HT risk patients, there was a steady decline in the rate of symptomatic (HTI=0 vs. HTI≥2: by 3.8%, p=0.120 vs. 14.3%, pp=0.864 vs. 19.5%, p<0.001).
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  9. 09HumanOther designEfficacy outcome

    In stroke patients with HTI=0, Cerebrolysin decreased mRS scores by 2.1%, without statistical significance.

    In plain wordsIn stroke patients with low bleeding risk, Cerebrolysin did not significantly change disability scores.

    Peptide
    Cerebrolysin
    Outcome
    No significant changemRS at low risk
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    mRS score reduction
    2.1%
    HTI=0
    p value for Cerebrolysin treatment effect on mRS score on day 90
    0.893
    Cerebrolysin treatment effect within HTI=0

    Source sentences

    Summary
    Likewise, Cerebrolysin treatment resulted in an overall decrease in the mRS scores (HTI=0 vs. HTI≥2: by 2.1%, p=0.893 vs. 63%, pp=0.634 vs. 19.2%, p<0.001).
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  10. 10HumanOther designEfficacy outcome

    In stroke patients with HTI≥2, Cerebrolysin decreased mRS scores by 63%.

    In plain wordsIn stroke patients with high bleeding risk, Cerebrolysin reduced disability scores.

    Peptide
    Cerebrolysin
    Outcome
    DecreasemRS at high risk
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    mRS score reduction
    63%
    HTI≥2
    p value for Cerebrolysin treatment effect on mRS score on day 90
    < 0.001
    Cerebrolysin treatment effect within HTI≥2

    Source sentences

    Summary
    Likewise, Cerebrolysin treatment resulted in an overall decrease in the mRS scores (HTI=0 vs. HTI≥2: by 2.1%, p=0.893 vs. 63%, pp=0.634 vs. 19.2%, p<0.001).
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  11. 11HumanOther designEfficacy outcome

    In stroke patients with HTI=0, Cerebrolysin increased favorable outcomes by 2%, without statistical significance.

    In plain wordsIn stroke patients with low bleeding risk, Cerebrolysin did not significantly increase favorable outcomes.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeFavorable outcome at low risk
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Favorable outcome increase
    2%
    HTI=0
    p value for Cerebrolysin treatment effect on favorable outcome on day 90
    0.634
    Cerebrolysin treatment effect within HTI=0

    Source sentences

    Summary
    Likewise, Cerebrolysin treatment resulted in an overall decrease in the mRS scores (HTI=0 vs. HTI≥2: by 2.1%, p=0.893 vs. 63%, pp=0.634 vs. 19.2%, p<0.001).
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.
  12. 12HumanOther designEfficacy outcome

    In stroke patients with HTI≥2, Cerebrolysin increased favorable outcomes by 19.2%.

    In plain wordsIn stroke patients with high bleeding risk, Cerebrolysin increased favorable outcomes.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFavorable outcome at high risk
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Favorable outcome increase
    19.2%
    HTI≥2
    p value for Cerebrolysin treatment effect on favorable outcome on day 90
    < 0.001
    Cerebrolysin treatment effect within HTI≥2

    Source sentences

    Summary
    Likewise, Cerebrolysin treatment resulted in an overall decrease in the mRS scores (HTI=0 vs. HTI≥2: by 2.1%, p=0.893 vs. 63%, pp=0.634 vs. 19.2%, p<0.001).
    3 context sentences
    Summary · context
    It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
    Summary · context
    Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score.
    Summary · context
    The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.